Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICCASSO: Pembrolizumab and Maraviroc in Refractory MSS mCRC
NCT03274804Phase 1Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of maraviroc and pembrolizumab in metastatic colorectal cancer (mCRC), sponsored by Heidelberg University Hospital. Primary endpoint: Feasibility Rate of a Combined Therapy. Started Apr 2018; status: completed.
02
Drugs
maravirocpembrolizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03274804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274804.